Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
MEDICAL USE OF GLUFOSFAMIDE IN ANTI-CANCER
Document Type and Number:
WIPO Patent Application WO/2019/105149
Kind Code:
A1
Abstract:
Glufosfamide or analogs thereof have specific inhibitory effects on a cell having a specific gene mutation, in particular on a DNA repair-damaged cell. The cell or tissue has at least one gene mutation or more gene mutations in BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP and ERCC5. The analogs refer to esters obtained by means of esterification of one hydroxyl group or more hydroxyl groups in glufosfamide molecules with organic acids and inorganic oxy-acids; esters obtained by means of esterification of one hydroxyl group or more hydroxyl groups in glufosfamide molecules with amino acids; and salts obtained by means of a reaction of the glufosfamide molecule with acids. For this, pharmaceutical use of glufosfamide or analogs thereof for treating tumors and cancer diseases in cancer patients having the specific gene mutation(s) as mentioned above is provided.

Inventors:
DUAN JIANXIN (CN)
LI ANRONG (US)
MENG FANYING (US)
JUNG DONALD·T (US)
Application Number:
PCT/CN2018/111230
Publication Date:
June 06, 2019
Filing Date:
October 22, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHENZHEN ASCENTAWITS PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
A61K31/7024
Domestic Patent References:
WO2016197012A12016-12-08
WO2008034039A22008-03-20
Foreign References:
US20170157161A12017-06-08
CN105030798A2015-11-11
CN107106687A2017-08-29
Attorney, Agent or Firm:
SHANGHAI DANRONG & ZONGDE INTELLECTUAL PROPERTY AGENCY CO., LTD. (CN)
Download PDF: